ストックスクリーナーアプリを入手
4.19
2.33%
-0.10
アフターアワーズ：
4.09
-0.10
-2.39%
Briacell Therapeutics Corp (BCTX) 最新ニュース
(BCT) Pivots Trading Plans and Risk Controls (BCT:CA) - news.stocktradersdaily.com
BriaCell Therapeutics (BCTX) Sees Stock Boost On Promising Trial News - Stocks Telegraph
In Brief: BriaCell’s Breast Cancer Cell Therapy Boosts Survival In Phase II - insights.citeline.com
BriaCell Stock Rises On Positive Survival Data From Study In Cancer Patients: Retail Gets More Bullish - NewsBreak: Local News & Alerts
BriaCell Therapeutics Corp. - Baystreet.ca
BCTXBriacell Therapeutics Corp Latest Stock News & Market Updates - Stock Titan
BriaCell therapy improves breast cancer survival rate | 2025-04-16 | Investing News - Stockhouse
BriaCell (BCTX) Reports Promising Phase 2 Survival Data in Breas - GuruFocus
BriaCell Says Breast Cancer Therapy Shows Positive Survival Data; Shares Rise - marketscreener.com
BriaCell (BCTX) Reports Promising Phase 2 Survival Data in Breast Cancer Study | BCTX Stock News - GuruFocus
BriaCell’s Phase 2 Study Shows Promising Survival Data in Breast Cancer - TipRanks
BriaCell reports survival boost in breast cancer study - Investing.com
BriaCell Phase 2 Survival Data Beats Leading Standard in HR+ Breast Cancer - GlobeNewswire
Clinical Trial Success: BriaCell's Treatment Outperforms Standard Therapy in Advanced Breast Cancer - Stock Titan
(BCT) Investment Report (BCT:CA) - news.stocktradersdaily.com
(BCT) Optimized Trading Opportunities (BCT:CA) - news.stocktradersdaily.com
Briapro Therapeutics develops anti-B7-H3 antibodies - BioWorld MedTech
BriaPro Advances Novel Anti-Cancer Antibody Development - TipRanks
BriaCell's Subsidiary, BriaPro, Develops Novel Antibodies to Anti-Cancer Target B7-H3 - GlobeNewswire
Game-Changing Cancer Treatment: BriaCell's New Antibodies Target Multiple Solid Tumors - Stock Titan
Virtu Financial LLC Makes New $27,000 Investment in BriaCell Therapeutics Corp. (NASDAQ:BCTX) - Defense World
BriaCell Therapeutics (OTCMKTS:BCTXF) Shares Up 4% – Here’s What Happened - Defense World
BriaCell Therapeutics (NASDAQ:BCTX) Trading 4% Higher – Time to Buy? - Defense World
(BCT) Technical Patterns and Signals (BCT:CA) - news.stocktradersdaily.com
BriaCell Therapeutics: Stocks Undervalued by Analyst Consensus on TSX (BCT) - The Globe and Mail
BriaCell Therapeutics Corp. (NASDAQ:BCTXW) Short Interest Update - Defense World
BriaCell to Present Clinical and Preclinical Data at the 2025 AACR Conference - GlobeNewswire
BriaCell to Showcase Cancer Immunotherapy Advances at AACR 2025 - TipRanks
New Clinical Data: BriaCell's Registration Trial Results for Advanced Breast Cancer Treatment - Stock Titan
Where Will Rigetti Computing Stock Be in 1 Year? - The Globe and Mail
Dan Ives Is Pounding the Table on Microsoft Stock. Should You Buy the Dip? - The Globe and Mail
Quantum Gamble? Is IonQ's Stock an Opportunity or a Mirage? - The Globe and Mail
(BCT) Stock Evaluation Report (BCT:CA) - Stock Traders Daily
(BCT) Market Dynamics and Trading Signals (BCT:CA) - news.stocktradersdaily.com
What To Expect From Carnival’s (CCL) Q1 Earnings - The Globe and Mail
BriaCell’s Phase 3 Breast Cancer Trial Proceeds After Safety Review By Investing.com - Investing.com South Africa
Stocks In Play: BriaCell Therapeutics Corp By Baystreet.ca - Investing.com Canada
(BCT) Technical Analysis and Trading Signals (BCT:CA) - Stock Traders Daily
BriaCell Therapeutics Corp - Baystreet.ca
Stocks in play: BriaCell Therapeutics Corp - The Globe and Mail
BriaCell Therapeutics Says Data Safety Monitoring Board Recommends Continuation of Phase 3 Trial in Metastatic Breast Cancer - MarketScreener
BriaCell’s Phase 3 Metastatic Breast Cancer Study Receives Positive DSMB Review - TipRanks
BriaCell’s Phase 3 Breast Cancer Trial Proceeds After Safety Review - Investing.com
Second Data Safety Monitoring Board Issues Positive - GlobeNewswire
Major Milestone: BriaCell's Breast Cancer Immunotherapy Passes Critical Safety Review in Phase 3 Trial - Stock Titan
3 Reasons DRS is Risky and 1 Stock to Buy Instead - The Globe and Mail
Briacell Therapeutics Corp reports results for the quarter ended January 31Earnings Summary - TradingView
BriaCell Therapeutics Corp. (NASDAQ:BCTXW) Sees Significant Growth in Short Interest - Defense World
Briacell Therapeutics Corp expected to post a loss of $1.12 a shareEarnings Preview - TradingView
3 Industrials Stocks Walking a Fine Line - The Globe and Mail
BriaCell Therapeutics (OTCMKTS:BCTXF) Trading 0.3% Higher – Here’s Why - Defense World
BriaCell Therapeutics Reports Continued Financial Challenges - TipRanks
BriaCell subsidiary reports interim financial results By Investing.com - Investing.com Australia
BriaCell Therapeutics Corp. SEC 10-Q Report - TradingView
BriaCell subsidiary reports interim financial results - Investing.com India
0.15%
4.32%
大文字化:
|
ボリューム (24 時間):